Texas MPN Workshop 2022 | The impact of ruxolitinib on the long-term survival of patients with MF
Tiziano Barbui
• 22 Aug 2022
Tiziano Barbui, MD, Bergamo Hospital Research Foundation, Bergamo, Italy, shares some insights into the impact of ruxolitinib on the long-term survival of patients with myelofibrosis (MF). Prof. Barbui first highlights the important role of transplantation in MF, and then goes on to share some real-world data on the use of this agent. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
